The Guaifenesin market in the US continued to slide through the first half of November, extending the big drop in October as the oversupply situation persisted across the supply chain. Market sentiment was soft for Guaifenesin as importers, formulators and distributors were faced with a plenty stock and lack of demand downstream. With surplus building up at origin markets, US buyers were very cautious in their buying, expecting further reductions in Guaifenesin prices in the coming weeks.
October was a big month for Guaifenesin, with prices falling to USD ****/MT on a CFR Los Angeles basis, a *.*** monthly drop. This Guaifenesin price decline continued into early November as US buyers delayed bulk purchases, not wanting to commit to large volumes in a weakening global market. The correction was amplified by competitive exports from major producing regions where suppliers had excess stock and limited demand absorption. Logistics...
Leave a Comment
Comments (0)